key: cord-0963026-eo87uv5u
authors: Cinkilic, Okan; Anft, Moritz; Blazquez-Navarro, Arturo; Meister, Toni L.; Roch, Toralf; Stervbo, Ulrik; Pfaender, Stephanie; Westhoff, Timm H.; Babel, Nina
title: Inferior humoral and sustained cellular immunity against wild type and omicron VOC in hemodialysis patients immunized with three SARS-CoV-2 vaccine doses compared to four doses
date: 2022-03-14
journal: Kidney Int
DOI: 10.1016/j.kint.2022.03.005
sha: 950db09cbda7ad34821e254d79de09826119c717
doc_id: 963026
cord_uid: eo87uv5u

nan

Studies analyzing humoral immunity against the most recent SARS-CoV-2 variant of concern (VOC) omicron (B.1.1.529) in general population demonstrate a clear benefit of an additional boost with respect to neutralization capacity 1 , and several national health authorities recommend the fourth vaccination dose. For immunocompromised patients including renal transplant and hemodialysis patients, the fourth vaccination is of special relevance.

The aim of the present study was to evaluate the immunogenicity of a fourth mRNA-based vaccination (BNT162b2, Pfizer-BioNTech) in comparison to three vaccination doses in hemodialysis patients. We analyzed the adaptive immunity against SARS-CoV-2 wild type (WT) and omicron VOCs in a cohort of hemodialysis patients (HDP, n=40) following third vaccination dose as compared to fourth dose. Titers of binding antibodies as well as neutralizing antibodies against WT and omicron were estimated by ELISA and SARS-CoV-2 spike-protein (S-protein) pseudovirus assays, respectively. T cell immunity reactive against WT-and omicron-derived S-protein was analyzed by multiparameter flow cytometry. The analyses were performed 4-6 weeks following the third doses in all patients (HDP3x; n=40). Patients who received an additional doses after 6-8 weeks (HDP4x; n=19) were analyzed 4-6 weeks thereafter and patients who received only three doses (HDP3xT12; n=21) were analyzed after 12 weeks (Suppl. Figure S1 ).

All patients demonstrated seroconversion with significantly higher titers of binding and omicron-specific neutralizing antibodies in HDP4x group as compared to HDP3x ( Figure 1A -B). As expected, fourth vaccination led to a significant increase in titers of omicron-specific neutralizing antibodies (HDP4x,T2), whereas a significant decline in neutralizing antibody titers was observed between 6 and 12 weeks following third vaccination (HDP3x, T2), if the fourth dose was not applied ( Figure 1C and Suppl. Figure S1 ). Of interest, we demonstrated a significant correlation between titers of binding and omicron-specific neutralizing antibodies ( Figure 1D ) with ROC demonstrating a higher AUC for WT as compared to omicron ( Figure  1E ). Notably, we did not detect significant differences in humoral or cellular immunity in patients, which received COVID-19 vector vaccine from Johnson&Johnson or mRNA vaccine BNT162b2 as a third vaccine doses. (Figures 1 C,F,G) as it was previously reported 2 .

In contrast to the humoral immunity, the cellular immunity remained stable in follow up, without magnitude increase of WT or omicron S-protein specific T cells in HDP4x group ( Figure 1F -G).

In line with the improved seroconversion rate in transplant patients [3] [4] [5] , our data demonstrate an improved omicron-specific humoral immunity following fourth mRNA vaccination dose as compared to three-dose vaccination regimen in hemodialysis patients. Even though adequate neutralization titers have been observed following third dose, the significant titer decline observed in follow up justifies the fourth dose in this vulnerable population subgroup. samples and clinical data for this project. We would like to acknowledge the excellent assistance of dialysis staff (Jacqueline Wellenkötter and Tina Giglio) of Dialysezentrum Schwerte as well as the expertise and technical assistance of immune diagnostic laboratory (Sviatlana Kaliszczyk, Patrizia Wehler, Sarah Skrzypczyk, Eva Kohut, Julia Kurek, Jan Zapka) of Center for Translational Medicine at Marien Hospital Herne. This work was supported by grants of Mercator Foundation, COVIDDataNet.NRW, and AIF/ZIM project EpiCov.

Data availability statement: The data will be available upon request. (HDP4x, T2) . Correlation between titers of SARS-CoV-2 wild type binding and omicron-specific neutralizing antibodies (D) and ROC curve (E) for the predictive capacity of binding antibody titers against wild type glycoprotein S for strong (>100 ND50) wildtypespecific (blue) and omicron-specific (yellow) neutralizing response, including the value for the area under the curve (AUC). (F,G) Isolated PBMCs from hemodialysis patients, vaccinated with three doses (HDP3x, n=19) or four doses (HDP4x, n=18), were stimulated for 16 h with 1 µg/ml SARS-CoV2 OPP from wild type (WT, left boxplots) or the mutated regions of SARS-CoV-2 omicron lineage (O, right boxplots). SARS-CoV-2 reactive T helper cells were identified as Life/Dead-Marker -CD3 + CD4 + CD137 + CD154 + (F) and SARS-CoV-2 reactive cytotoxic T cells were identified as Life/Dead-Marker -CD3 + CD8 + CD137 + (G).

In all boxplots, red corresponds to the patients who received only three doses and blue to those who received all four doses; light colors refer to the time point after the third dose, while dark colors denote the time point after the fourth dose or 12 weeks after the third. Groups were compared using two-sided, unpaired Mann-Whitney-U-Test; except for (C), where Wilcoxon signed-rank paired test was employed; the correlation (D) was evaluated employing the Pearson correlation coefficient. P-values ≤ 0.050 were defined significant. 

mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant

Antibody Response to a Fourth Messenger RNA COVID-19 Vaccine Dose in Kidney Transplant Recipients: A Case Series

Assessment of 4 Doses of SARS-CoV-2 Messenger RNA-Based Vaccine in Recipients of a Solid Organ Transplant

A vector-based vaccine dose after three doses of mRNA-based COVID-19 vaccination does not substantially improve humoral SARS-CoV-2 immunity in renal transplant recipient

We feel deep gratitude to the patients who donated their blood